Avanos Medical, Inc. reports developments as a medical technology company that develops, manufactures and markets medical device solutions for Specialty Nutrition Systems and Pain Management and Recovery. Its news commonly covers operating results, segment growth, enteral feeding products, non-opioid surgical pain and recovery products, infusion pumps, radiofrequency ablation solutions and cryo-pneumatic compression systems.
Company updates also include Medicare payment and regulatory reimbursement developments for ON-Q, AmbIT and Game Ready, collaborations for outpatient and interventional pain workflows, investor conference presentations, cost and transformation initiatives, and governance matters such as board nominations and shareholder agreements.
Avanos (NYSE: AVNS) reported Q1 2026 results and agreed to be acquired by affiliates of American Industrial Partners for an enterprise value of $1.272 billion. Q1 net sales were $182.2 million (up 8.8%). Specialty Nutrition Systems sales rose by $22.9 million to $124.0 million. GAAP net income was $5.1 million; adjusted net income was $10.6 million. Cash used in operations was an outflow of $12.3 million, and total debt was $98.2 million as of March 31, 2026.
Avanos (NYSE: AVNS) agreed to be acquired by affiliates of American Industrial Partners for an enterprise value of approximately $1.272 billion. Avanos stockholders will receive $25.00 per share in cash, a ~72.1% premium to the April 13, 2026 close and an ~82.8% premium to the 30-day VWAP.
The transaction, unanimously approved by the Avanos board, is expected to close in the second half of 2026, is not subject to a financing condition, and will result in Avanos becoming a private company.
Avanos Medical (NYSE: AVNS) will present at the 2026 Citizens Life Sciences Conference on March 11, 2026. CEO Dave Pacitti and CFO Scott Galovan will appear in a fireside chat at ~1:05 p.m. ET.
A live webcast will be available and later archived on the company's Investors webpage.
Avanos Medical (NYSE: AVNS) announced it will nominate James L. Cunniff and William P. Burke as independent directors for election at the Company’s 2026 Annual Meeting, subject to customary background checks.
Avanos entered into a cooperation agreement with Bradley L. Radoff in connection with the nominations; the agreement will be filed as an exhibit to a Current Report on Form 8-K. The Company will include its formal board recommendation in its definitive proxy materials to be filed with the SEC. The 2026 meeting date is not yet scheduled.
Avanos Medical (NYSE: AVNS) reported fourth-quarter and full-year 2025 results on Feb 24, 2026, with full-year net sales of $701.2M and adjusted diluted EPS of $0.94. The company delivered organic growth in strategic segments, recorded a $77.0M goodwill impairment, and expects $15–20M of incremental annualized savings by end of 2026.
Q4 net sales were $180.9M, adjusted EBITDA for the year was $86.8M, year-end cash totaled $89.8M, and net debt was $10.7M.
Avanos Medical (NYSE: AVNS) will webcast a conference call to discuss fourth quarter and full year 2025 financial results on Feb. 24, 2026 at 9:00 a.m. ET. A news release with results will be issued before market open that day.
The call will be hosted by CEO Dave Pacitti and SVP/CFO Scott Galovan. Investors can join by phone, register for instant dial-in, or listen to a simultaneous webcast via the Avanos investors website. A replay will be available about two hours after the call and remain accessible for one week.
Avanos (NYSE: AVNS) announced that CMS' 2026 OPPS/ASC Final Rule maintains separate NOPAIN Act Medicare payment for the Avanos ON-Q and ambIT infusion pumps and adds Game Ready GRPro 2.1 effective Jan. 1, 2026.
CMS assigned unique HCPCS codes and published payment limits of $2,008.72 for ON-Q and ambIT, and $1,997.16 for Game Ready when medically necessary and used with a covered surgical procedure.
Avanos (NYSE: AVNS) and Siemens Healthineers announced a strategic co-marketing agreement to integrate Avanos radiofrequency ablation (RFA) technologies with Siemens mobile C-arm imaging systems for outpatient and interventional pain management.
The collaboration targets ambulatory surgery centers, hospitals, and interventional pain practices in the U.S., focusing on joint education, sales training, and marketing to promote a combined workflow that aims to improve procedural accuracy, efficiency, and consistency in patient care.
Avanos Medical (NYSE: AVNS) announced that CEO Dave Pacitti will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13, 2026 at approximately 2:15 p.m. PST. A live webcast will be available on the company Investors website and the presentation will be archived there for later viewing.
Avanos Medical (NYSE: AVNS) reported Q3 2025 results on Nov 5, 2025: total net sales of $177.8 million (+4.3% YoY) and a net loss of $1.4 million (vs. income of $5.9M a year ago). Adjusted net income was $10.1 million and adjusted diluted EPS was $0.22. The company closed the acquisition of Nexus Medical and delivered double‑digit volume growth in its Specialty Nutrition Systems (SNS) segment. Management raised and narrowed full‑year 2025 guidance to $690–700 million revenue and adjusted diluted EPS of $0.85–0.95. The company recorded a $77.0 million goodwill impairment earlier in 2025 and had $70.5 million cash and $102.8 million net debt at Sept 30, 2025.